TABLE 3.

Clinical and laboratory characteristics of deaths associated with Viridans Group Streptococci bacteraemia.

Patient number	Age category†	Gender	Nutrition‡	HIV status	Diagnosis	Underlying condition	CRP	WBC	SIRS score	pSOFA	Antibiotic susceptibility	Empiric antibiotic used	Time interval in days (culture to outcome)	Time to positivity of culture (hours)
1	Neonate	F	Underweight	Neg	Pneumonia	Premature	1	8.73	2	8	Sensitive	Ampicillin/gentamycin	7	10
2	Neonate	M	Underweight	Neg	NOS	Premature	19	3.13	NC	NC	Resistant ampicillin	Unknown	16	12
3	Neonate	F	Normal	Neg	NOS	DiGeorge/CHD	23	33.8	NC	NC	Not done	Unknown	19	10
4	Neonate	F	Normal	Neg	NOS	Spina bifida	8	11.8	NC	NC	Not done	Unknown	10	6
5	Infant	M	Underweight	Neg	Pneumonia	Trisomy21/CHD	1	9.95	2	5	Resistant cefotaxime	Meropenem	1	8
6	Infant	F	Underweight	Pos	NOS	BPD	102	8.96	0	5	Sensitive	Meropenem/vancomycin	44	CSF (no time stated)
7	Infant	F	Underweight	Neg	Pneumonia	Premature	18	7.32	NC	NC	Sensitive	Unknown	1	12
8	Child	F	Normal	Neg	Pneumonia	Cerebral palsy	300	15.4	NC	NC	Sensitive	Unknown	1	19

CRP, C-reactive protein; WBC, white blood cell; SIRS, systemic inflammatory response syndrome; pSOFA, paediatric sequential organ failure assessment; Neg, negative; Pos, positive; NOS, nosocomial sepsis; CHD, congenital heart disease; BPD, bronchopulmonary dysplasia; NC, not calculable (missing data); F, female; M, male.

^†, Neonate, infant child;

^‡, Normal underweight stunted wasted.